Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis

Ruxolitinib cream 1.5% (OPZELURATM) is a topical formulation of ruxolitinib, a potent, selective inhibitor of Janus kinase (JAK)1 and JAK2. The targeting of these kinases is associated with therapeutic benefits in patients with atopic dermatitis (AD). In two identically designed, multinational, phase III studies in patients aged > 12 years with mild to moderate AD, ruxolitinib cream 1.5% improved measures of disease severity, pruritus and sleep disturbance relative to vehicle cream when applied twice daily for 8 weeks. Disease severity was controlled for the next 44 weeks when applied as needed to active lesions. Ruxolitinib cream 1.5% was well tolerated in this patient population; its safety profile was similar to that of vehicle cream over the short term, with the types of treatment-emergent adverse events typical of those seen in the vehicle-controlled period over the longer term. Moreover, application site treatment-emergent adverse events indicative of skin tolerability issues (e.g. stinging/burning sensation) were infrequent and no safety findings suggestive of systemic JAK inhibition were identi-fied. Although further longer-term data would be of use, ruxolitinib cream 1.5% provides an alternative to established topical agents (e.g. corticosteroids and calcineurin inhibitors) for the treatment of mild to moderate AD in adults and adolescents.

Automated summary

Ruxolitinib cream 1.5% is an alternative topical agent for the treatment of mild to moderate atopic dermatitis (AD) in adults and adolescents. It showed improvements in measures of disease severity, pruritus, and sleep disturbance when applied twice daily for 8 weeks, and disease severity was controlled for the next 44 weeks. Ruxolitinib cream 1.5% was well tolerated and had a similar safety profile to the vehicle cream.